Trial reportCancer2012
Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity.
Trial report in Cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 48 citations in OpenAlex.
- Participation in an occupational therapy referral program for children with retinoblastoma.Journal of pediatric rehabilitation medicine · 2016Trial
- Global, regional, and national burden and changing trends of hepatoblastoma and retinoblastoma from 1990 to 2021, and projections until 2050: findings from the Global Burden of Disease Study 2021.Translational pediatrics · 2026Article
- The Impact of Tumor Laterality (Unilateral vs. Bilateral) on Presentation and Management Outcome in Patients with Retinoblastoma.Journal of clinical medicine · 2024Article
- An exploratory study of sleep habits in school-aged survivors of retinoblastoma.Sleep medicine · 2023Article
- The Development of New Methodology for Determination of Vincristine (VCR) in Human Serum Using LC-MS/MS-Based Method for Medical Diagnostics.Molecules (Basel, Switzerland) · 2022Article
- Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study.The British journal of ophthalmology · 2022Article
- Review: New horizons in retinoblastoma treatment: an updated review article.Molecular vision · 2022Review
- Review
- Cognitive and Adaptive Functioning in Youth With Retinoblastoma: A Longitudinal Investigation Through 10 Years of Age.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Article
- Cross-species identification of PIP5K1-, splicing- and ubiquitin-related pathways as potential targets for RB1-deficient cells.PLoS genetics · 2021Article
- microRNA-222-Mediated VHL Downregulation Facilitates Retinoblastoma Chemoresistance by Increasing HIF1α Expression.Investigative ophthalmology & visual science · 2020Article
- Clotam enhances anti-proliferative effect of vincristine in Ewing sarcoma cells.Apoptosis : an international journal on programmed cell death · 2019Article
- A longitudinal investigation of parenting stress in caregivers of children with retinoblastoma.Pediatric blood & cancer · 2017Article
- Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Article
- Patients with retinoblastoma and chromosome 13q deletions have increased chemotherapy-related toxicities.Pediatric blood & cancer · 2016Article
- Lessons from Retinoblastoma: Implications for Cancer, Development, Evolution, and Regenerative Medicine.Trends in molecular medicine · 2016Review
- Article
- Management of retinoblastoma in children: current status.Paediatric drugs · 2015Review
- Developmental and adaptive functioning in children with retinoblastoma: a longitudinal investigation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Article
- Safety of ultrasound contrast agents in the pediatric oncologic population: a single-institution experience.AJR. American journal of roentgenology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
backgroundNew, effective chemotherapeutic agents are needed for intraocular retinoblastoma.
methodsThis institutional clinical trial sought to estimate the rate of response to 2 courses of vincristine and topotecan (VT) window therapy in patients with bilateral retinoblastoma and advanced disease (Reese-Ellsworth group IV or V) in at least 1 eye. The topotecan dose started at 3 mg/m(2) /day for 5 days and was adjusted to target a systemic exposure of 140 ± 20 ng/mL · hour. The vincristine dose was 0.05 mg/kg for patients <12 months of age and 1.5 mg/m(2) for those >12 months of age at diagnosis.
resultsFrom February 2005 to June 2010, 27 patients received VT window therapy. Median age at enrollment was 8.1 months (range, 0.7-22.1 months). Twenty-four patients (88.9%) responded to window therapy (95% confidence interval = 71.3%-96.9%). Hematologic toxicity comprised grade 4 neutropenia (n = 27), grade 3 anemia (n = 19), and grade 3/4 thrombocytopenia (n = 16). Thirteen patients had grade 3 nonhematologic toxicity. Granulocyte colony-stimulating factor support was added after 10 patients had been treated, and it significantly reduced the duration of grade 4 neutropenia (median, 7 vs 24 days; P < .001). Pharmacokinetic studies showed rapid changes in topotecan clearance rates during the first year of life.
conclusionsThe combination of topotecan and vincristine is effective for the treatment of advanced intraocular retinoblastoma. Granulocyte colony-stimulating factor treatment alleviates the duration of grade 4 neutropenia. Appropriate topotecan starting doses for patients 0-3, 3-6, 6-9, 9-12, and >12 months of age are specified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.